Evidence map›Paper›PMID 27153273›Full record

ArticleNature biotechnology2016

Regulate genome-edited products, not genome editing itself.

Dana Carroll, Alison L Van Eenennaam, Jeremy F Taylor, Jon Seger, Daniel F Voytas

Abstract readComment
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Genome Editing: Past, Present, and Future.The Yale journal of biology and medicine · 2017
    Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Dana CarrollDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID 0000-0002-3241-3331
Alison L Van EenennaamDepartment of Animal Science, University of California, Davis, California, USA.
Jeremy F TaylorDivision of Animal Sciences, University of Missouri, Columbia, Missouri, USA.
Jon SegerDepartment of Biology, University of Utah, Salt Lake City, Utah, USA.
Daniel F VoytasDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Optimizing Genome Engineering with Targetable NucleasesR01GM078571 · NIGMS · UNIVERSITY OF UTAH · PI CARROLL, DANA · 2006 to 2017
$4.3M
NIGMS NIH HHS R01 GM078571
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene EditingGenomeBase SequenceHumansRNA Editing

Identifiers

PMID27153273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.